Atherosclerosis as a systemic disease;La aterosclerosis como enfermedad sistémica

Revista Espanola de Cardiologia

Volumn 60, Issue 2, 2007, Pages 184-195

  Lahoz, Carlos ^a   Mostaza, José M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Ankle brachial index; Atherosclerosis; Inflammation; Risk factors

Indexed keywords

AMYLOID A PROTEIN; ANTITHROMBOCYTIC AGENT; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FIBRINOPEPTIDE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; RAMIPRIL; SIMVASTATIN; VON WILLEBRAND FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE DISTRIBUTION; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; RISK FACTOR; SMOKING; SPAIN; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; AGE; BLOOD; BLOOD PRESSURE MEASUREMENT; DIABETIC ANGIOPATHY; FEMALE; MALE; METHODOLOGY;

AGE FACTORS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE DETERMINATION; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MYOCARDIAL INFARCTION; RISK FACTORS; SMOKING; SPAIN;

EID: 33947579410     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13099465     Document Type: Article

References (63)

1. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995; 92:1355-74.
2. Viles-González JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197-207.
3. Llacer A, Fernández-Cuenca R. Mortalidad en España en 1999 y 2000 (I). Bol Epidemiol Semanal. 2003;11:121-20.
4. Llacer A, Fernández-Cuenca R. Mortalidad en España en 1999 y 2000 (II). Bol Epidemiol Semanal. 2003;11:121-32.
5. Villar AF, Banegas JR, Rodríguez AF, Del Rey CJ. Mortalidad cardiovascular en España y sus comunidades autónomas (1975-1992). Med Clin (Barc). 1998;110:321-27.
6. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18:1231-48.
7. Villar-Álvarez F, Banegas JR, Mata J, Rodríguez-Artalejo F. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Majadahonda: Ergón; 2003.
8. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-92.
9. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MR-FIT). JAMA. 1986;256:2823-8.
10. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74:1-12.
11. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
13. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.
14. Sánchez-Chaparro MA, Román-García J, Calvo-Bonacho E, Gómez-Larios T, Fernández-Meseguer A, Sainz-Gutiérrez JC, et al. Prevalence of cardiovascular risk factors in the Spanish working population. Rev Esp Cardiol. 2006; 59:421-30.
15. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988; 8:207-11.
16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
17. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598-615.
18. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-64.
19. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.
20. Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, De la Cruz-Troca JJ, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002;20:2157-64.
21. Jacobs DR, Adachi H, Mulder I, Kromhout D, Menotti A, Nissinen A, et al. Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study. Arch Intern Med. 1999;159:733-40.
22. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317:1303-9.
23. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease: a meta-analysis of epidemiologic studies. N Engl J Med. 1999;340:920-6.
24. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985;313:1511-14.
25. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161:1717-23.
26. Mostaza JM, Lahoz C. Tablas de riesgo para diabéticos ¿Son realmente necesarias? Med Clin (Barc). 2006;126:495-6.
27. Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study. Am Heart J. 1993;125:863-72.
28. Grand A, Termoz A, Fichter P, Ghadban W, Velon S, Abdulrahman O, et al. Myocardial infarction in the elderly. Comparison between 2 groups of patients over 75 and under 65 years of age. Ann Cardiol Angeiol (Paris). 1997;46:561-7.
29. Khoury Z, Schwartz R, Gottlieb S, Chenzbraun A, Stern S, Keren A. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. Am J Cardiol. 1997;80:1429-33.
30. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA. 1983;250:2942-6.
31. Sandercock PA, Warlow CP, Jones LN, Starkey IR. Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ. 1989;298:75-80.
32. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke. 1992;23:1250-6.
33. Bogousslavsky J, Van MG, Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 1988;19:1083-92.
34. Caicoya M, Corrales C, Lasheras C, Cuello R, Rodríguez T. Asociación entre accidente cerebrovascular y enfermedad arterial periférica: estudio de casos y controles en Asturias, España. Rev Clin Esp. 1995;195:830-5.
35. Criqui MH, Denenberg Jr, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2:221-6.
36. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-6.
37. Lujan S, Puras E, López-Bescos L, Belinchon JC, Gutiérrez M, Guijarro C. Occult vascular lesions in patients with atherothromboric events: the AIRVAG cohort. Eur J Vasc Endovasc Surg. 2005;30:57-62.
38. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
39. Mostaza JM, Vicente I, Taboada M, Laguna F, Echaniz A, García-Iglesias F, et al. La aplicación de las tablas del SCORE a varones de edad avanzada triplica el número de sujetos clasificados de alto riesgo en comparación con la función de Framingham. Med Clin (Barc). 2005;124:487-90.
40. Mostaza JM, Lahoz C. Tablas para la estimación del riesgo cardiovascular. ¿Todavía muchos interrogantes? Med Clin (Barc). 2006;126:535-36.
41. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105:1135-43.
42. Smith GD, Timpson N, Lawlor DA. C-reactive protein and cardiovascular disease risk: still an unknown quantity? Ann Intern Med. 2006;146:70-1.
43. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004;29:439-93.
44. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107:363-9.
45. Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, Polak JF, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662-7.
46. Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation. 2002;106:1189-91.
47. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8.
48. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
49. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21-9.
50. Mostaza JM, Vicente I, Cairols M, Castillo J, González-Juanatey JR, Pomar JL, et al. Índice tobillo-brazo y riesgo cardiovascular. Med Clin (Barc). 2003;121:68-73.
51. Vicente I, Lahoz C, Taboada M, García A, San Martín MA, Terol I, et al. Prevalencia de un índice tobillo-brazo anormal en relación con el riesgo cardiovascular estimado por la función de Framingham. Med Clin (Barc). 2005;124:641-4.
52. Vicente I, Lahoz C, Taboada M, Laguna F, García-Iglesias F, Mostaza Prieto JM. Índice tobillo-brazo en pacientes con diabetes mellitus: prevalencia y factores de riesgo. Rev Clin Esp. 2006;206:225-9.
53. Lahoz C, Vicente I, Laguna F, García-Iglesias MF, Taboada M, Mostaza JM. Metabolic syndrome and asymptomatic peripheral artery disease in subjects over 60 years of age. Diabetes Care. 2006;29:148-50.
54. Lamina C, Meisinger C, Heid IM, Lowel H, Rantner B, Koenig W, et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J. 2006;27:2580-7.
55. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ. 1996;313:1440-4.
56. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999;19:538-45.
57. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617-24.
58. O'Hare AM, Katz R, Shlipak MG, Cushman M, Newman AB. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation. 2006;113:388-93.
59. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109:733-9.
60. Lahoz C, Mostaza JM. Índice tobillo-brazo: una herramienta útil para la estratificación del riesgo cardiovascular. Rev Esp Cardiol. 2006;59:647-9.
61. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26:3333-41.
62. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
63. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342:145-53.